|

GM-CSF with combination regimen Clinical Trials

1 actively recruiting trial

Also known as: Recombinant Human Granulocyte/Macrophage Colony-stimulating Factor

Pipeline

Phase 2: 1

Top Sponsors

  • Sun Yat-Sen University Cancer Center1

Indications

  • Neuroblastoma1
  • Cancer1

Other1 trial

Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.